Work Here?
About AbbVie
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
N/A
Headquarters
North Chicago, Illinois
Founded
1888
Overview
AbbVie is a biopharmaceutical company that focuses on discovering and developing medicines for serious health conditions. Its products target a variety of diseases, including those in immunology, oncology, virology, and neuroscience, as well as offering aesthetic treatments. AbbVie’s medicines work by providing specialized therapies that healthcare providers prescribe to patients in need. The company stands out from competitors due to its significant investment in research and development, totaling $50 billion, which helps maintain a strong pipeline of new treatments. AbbVie aims to improve patient care by addressing unmet medical needs and is committed to sustainability and responsible practices for long-term growth.
Simplify's Take
What believers are saying
- Collaboration with Xilio Therapeutics could lead to breakthroughs in targeted cancer treatments.
- Allergan Aesthetics' AA Signature Program enhances personalized medicine in the aesthetics industry.
- Skyrizi and Rinvoq's revenue growth indicates a robust immunology pipeline.
What critics are saying
- Increased competition from biosimilars may impact revenue from key drugs like Humira.
- Regulatory challenges in Europe could affect the aesthetics market.
- Patent expiration of key drugs poses a risk of significant revenue loss.
What makes AbbVie unique
- AbbVie excels in developing innovative treatments for serious health conditions globally.
- The company has a strong R&D focus, investing $50 billion to date.
- AbbVie's aesthetics market presence is bolstered by Allergan Aesthetics' diverse product offerings.
Help us improve and share your feedback! Did you find this helpful?
Company News
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013."I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S
The collaboration and option-to-licence agreement will include masked T-cell engagers and will combine AbbVie's capabilities in oncology with Xilio's proprietary tumour-activation technology.
AbbVie appoints CEO Robert A. Michael as chairman of the board of directors.
Arcus Capital Partners LLC makes new Investment in AbbVie Inc. (NYSE:ABBV).
Elser Financial Planning Inc makes new investment in AbbVie Inc. (NYSE:ABBV).
There are no jobs for AbbVie right now.
Find jobs on Simplify and start your career today
About AbbVie
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
N/A
Headquarters
North Chicago, Illinois
Founded
1888
There are no jobs for AbbVie right now.
Find jobs on Simplify and start your career today